Abstract 15680: Comparative Renal Safety and Efficacy of Baxdrostat vs Lorundrostat in Hypertensive Patients: A Systematic Review and Network Meta-Analysis
Abstract
Background: Hypertension remains a major therapeutic challenge with significant morbidity, requiring novel pharmacological options. Selective aldosterone synthase inhibitors (ASIs), particularly baxdrostat and lorundrostat, offer a potent approach to blood pressure control. However, their comparative renal safety profiles across varying dosages remain inadequately defined. We conducted a systematic review and network meta-analysis (NMA) comparing renal safety and antihypertensive efficacy of these agents against placebo. Research Question:Among patients with hypertension, how do baxdrostat and lorundrostat compare with placebo and with each other in terms of antihypertensive efficacy and renal safety across different dosing regimens? Methods: PubMed, Cochrane, and Google Scholar were searched for relevant RCTs till May 15, 2026. Outcomes included ≥30% eGFR decline, absolute eGFR change, hyponatremia, hyperkalemia, hypotension, and changes in seated systolic and diastolic blood pressure (SBP and DBP). A frequentist NMA was conducted on R (version 5.4.1) using netmeta package. Odds ratios (ORs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes were used. Treatments were ranked according to P-scores. Results: Ten RCTs comprising 3475 patients were included. For ≥30% eGFR decline, baxdrostat 2mg (OR 8.77 [4.26-18.05]), baxdrostat 1mg (OR 7.06 [3.15-15.85]), and lorundrostat 100mg (OR 3.08 [1.10-8.60]) significantly increased risk vs placebo; baxdrostat 2mg ranked the least safe (P-score 6.6%). Only baxdrostat 2mg produced a significant absolute eGFR reduction (MD 7.01 mL/min/1.73m 2 [2.60-11.42]; P-score 83.3%). Significant hyperkalemia was observed with lorundrostat 100mg (OR 7.64 [1.40-41.78]) and baxdrostat 2mg (OR 4.18 [1.23-14.16]), with lorundrostat 100mg ranking worst (P-score 14.2%). For hyponatremia, only lorundrostat 100mg reached significance (OR 2.67 [1.44-4.97]; P-score 21.1%). No significant hypotension was detected across doses, though baxdrostat 2mg ranked worst (P-score 15.5%). Lorundrostat 50mg (MD –9.42 [–13.75; –5.09]; P-score 86.9%) and baxdrostat 2mg (MD –8.54 [–11.74; –5.35]; P-score 81%) demonstrated the greatest SBP reductions. For DBP, lorundrostat 50mg ranked highest (MD –6.00 [–11.12; –0.88]; P-score 88.6%). Conclusion: Baxdrostat and lorundrostat effectively reduce SBP and DBP in hypertension but impose significant dose-dependent renal risks. Lorundrostat 50mg achieves optimal efficacy while maintaining a comparatively favorable renal safety profile. In contrast, baxdrostat 2mg conferred the highest renal risk, while lorundrostat 100mg carried the greatest hyperkalemia burden. These findings underscore the need for personalized, dose-conscious ASI selection to maximize cardiovascular benefit while minimizing renal harm.